Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The profitability profile demonstrates a strong overall upward trajectory, characterized by a period of margin compression in 2023 followed by a significant and sustained expansion across all key metrics. While gross profitability remained consistently positive, operating and net margins experienced a temporary dip before accelerating to record highs by early 2026.
- Gross Profit Margin
- A consistent and linear upward trend is observed, rising from 74.40% in March 2022 to 82.83% by March 2026. This steady growth suggests a persistent improvement in production efficiency or an increase in the pricing power of the product portfolio.
- Operating and Net Profit Margins
- Both metrics exhibit a V-shaped recovery pattern. Operating profit margin declined from 25.94% in early 2022 to a low of 18.42% in September 2023, while net profit margin fell to 15.36% in December 2023. Following this contraction, a sharp acceleration occurred; operating margin expanded to 43.63% and net profit margin climbed to 34.99% by March 2026. This suggests that an initial period of increased operational expenditure or investment transitioned into a phase of high operational leverage and increased profitability.
- Return on Equity (ROE)
- ROE shows significant volatility between 2022 and 2023, dropping from a high of 66.61% in June 2022 to a trough of 44.46% in September 2023. However, the metric recovered aggressively, reaching 81.02% by March 2026. The substantial gap between ROE and ROA indicates a high degree of financial leverage contributing to shareholder returns.
- Return on Assets (ROA)
- ROA mirrors the trend of the profit margins, experiencing a decline from 13.06% in March 2022 to a minimum of 8.19% in December 2023. A consistent recovery followed, with the ratio reaching 21.68% by March 2026, indicating an improved capacity to generate earnings from the company's asset base.
Return on Sales
Return on Investment
Gross Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Gross margin | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Gross profit margin = 100
× (Gross marginQ1 2026
+ Gross marginQ4 2025
+ Gross marginQ3 2025
+ Gross marginQ2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The period from March 31, 2022, to March 31, 2026, is characterized by a substantial increase in total revenue accompanied by a consistent expansion in profitability margins. Total revenue grew from 7,810 million USD to 19,799 million USD, while gross profit in absolute terms rose from 5,738 million USD to 16,222 million USD.
- Revenue Growth Patterns
- A sustained upward trajectory is evident, with significant acceleration occurring from June 2024 onward. While the first two years showed moderate growth with occasional quarterly fluctuations, the revenue scale increased more aggressively between June 2024 and December 2025, nearly doubling the quarterly revenue seen in early 2022.
- Gross Profit Margin Expansion
- The gross profit margin percentage exhibited a nearly linear increase throughout the analyzed timeframe. Starting at 74.40% in March 2022, the margin expanded steadily to reach a peak of 83.04% in December 2025. This represents an overall increase of approximately 864 basis points, indicating improved production efficiency or increased pricing power.
- Margin Stability and Recent Trends
- The expansion of the gross profit margin remained consistent across seventeen consecutive quarters. A slight normalization is observed in the final period ending March 31, 2026, where the margin dipped marginally to 82.83% from its peak, though it remains significantly higher than the levels recorded in the 2022-2023 period.
Operating Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Operating income | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2026
+ Operating incomeQ4 2025
+ Operating incomeQ3 2025
+ Operating incomeQ2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibits a distinct three-phase trajectory characterized by initial stability, a period of significant contraction, and a subsequent phase of aggressive expansion.
- Initial Stability and Contraction (2022–2023)
- From March 2022 through December 2022, the operating profit margin remained relatively stable, fluctuating within a narrow range between 24.65% and 25.94%. A downward trend emerged throughout 2023, culminating in a trough of 18.42% in September 2023. This decline occurred despite a general increase in quarterly revenue, indicating that operating expenses grew at a disproportionately faster rate than sales during this interval.
- Recovery and Accelerated Expansion (2024–2026)
- A consistent recovery began in March 2024, with the margin rising to 20.80% and steadily climbing throughout the year. Starting in 2025, the rate of margin expansion accelerated significantly. The operating profit margin grew from 28.74% in March 2025 to 43.63% by March 2026, representing a substantial increase in operational efficiency and profitability.
- Operating Leverage and Revenue Scaling
- The data reveals a strong positive correlation between revenue scaling and margin expansion in the latter half of the period. Between March 2024 and March 2026, revenue increased from 8.77 billion to 19.80 billion. During this same window, operating income rose from 2.51 billion to 8.92 billion. The fact that operating income grew at a faster pace than revenue demonstrates significant operating leverage, where a larger proportion of each additional dollar of revenue is converted into operating profit.
Net Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net profit margin = 100
× (Net income (loss)Q1 2026
+ Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Analysis of the quarterly financial performance indicates a strong trajectory of growth in both absolute earnings and operational efficiency. Revenue increased steadily from 7,810 million USD in March 2022 to 19,799 million USD by March 2026, reflecting a substantial expansion of the top line over the analyzed period.
- Net Profit Margin Trends
- The net profit margin exhibited a period of relative stability between 19.58% and 22.01% throughout most of 2022. A notable contraction occurred in the latter half of 2023, with margins dropping to a low of 15.36% in December 2023. This downturn coincided with a quarterly net loss of 57 million USD reported in September 2023, indicating a temporary volatility in profitability.
- Profitability Acceleration
- Following the contraction in 2023, a consistent and aggressive upward trend in profit margins is observed beginning in early 2024. The margin recovered to 17.08% in March 2024 and climbed steadily to reach 34.99% by March 2026. This trend suggests a significant improvement in operational leverage, where net income growth is outpacing revenue growth.
- Revenue and Net Income Correlation
- A strong positive correlation is evident between the scaling of revenue and the expansion of net margins in the final eight quarters. While revenue grew from 8,768 million USD in March 2024 to 19,799 million USD in March 2026, net income rose from 2,243 million USD to 7,396 million USD in the same period. The resulting increase in the net profit margin from 17.08% to 34.99% indicates enhanced cost efficiencies or a favorable shift in the product mix toward higher-margin offerings.
Return on Equity (ROE)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROE = 100
× (Net income (loss)Q1 2026
+ Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025)
÷ Total Eli Lilly and Company shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance from March 2022 through March 2026 is characterized by a period of initial volatility followed by an aggressive growth phase in both absolute profitability and capital efficiency. A notable transition occurs between 2023 and 2024, shifting from a contraction in return metrics to a period of sustained expansion.
- Net Income Trajectory
- Earnings exhibited significant fluctuations in the early stages, including a sharp decline to a loss of 57 million US dollars in September 2023. However, a robust recovery followed, with net income escalating from 2.24 billion US dollars in March 2024 to a peak of 7.39 billion US dollars by March 2026. This represents a substantial acceleration in profitability, particularly during the 2025 calendar year.
- Shareholders' Equity Expansion
- The equity base grew steadily from 9.33 billion US dollars in March 2022 to 31.19 billion US dollars by March 2026. While growth was gradual through 2023, a rapid increase in the equity base is observed starting in 2025, suggesting significant retained earnings or capital infusions that expanded the company's net asset value.
- Return on Equity (ROE) Performance
- ROE followed a U-shaped trajectory. Initially high at 65.69% in March 2022, the ratio trended downward to a low of 44.46% in September 2023, coinciding with the dip in net income. A subsequent reversal occurred in 2024, with ROE climbing steadily to surpass 70% by late 2024. This upward momentum continued through early 2026, reaching a peak of 81.02%. The fact that ROE increased while the equity base expanded indicates that net income growth significantly outpaced the growth of shareholders' equity, reflecting highly efficient capital utilization during the final two years of the period.
Overall, the period is marked by a successful scaling of operations where the increase in the capital base did not dilute profitability, but rather accompanied a surge in earnings that drove return on equity to historic highs.
Return on Assets (ROA)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROA = 100
× (Net income (loss)Q1 2026
+ Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of profitability metrics reveals a cyclical performance pattern characterized by an initial period of stability, a mid-term contraction, and a subsequent phase of significant acceleration. The Return on Assets (ROA) demonstrates a transition from moderate efficiency to high capital productivity over the observed period, reflecting a strong correlation between scaling assets and escalating net income.
- Asset Base Expansion
- Total assets exhibited a consistent upward trajectory, increasing from 46,919 million US dollars in March 2022 to 116,576 million US dollars by March 2026. A period of rapid expansion is noted between March 2024 and June 2025, during which the asset base grew by approximately 40%, indicating substantial capital investment and organizational scaling.
- Net Income Dynamics
- Net income experienced notable volatility during 2023, culminating in a net loss of 57 million US dollars in September 2023. This dip was followed by a robust recovery and an aggressive growth phase starting in 2024. Net income rose from 2,243 million US dollars in March 2024 to a peak of 7,396 million US dollars by March 2026, suggesting that revenue growth and margin expansion significantly outpaced the growth of the asset base in the latter half of the period.
- Return on Assets (ROA) Performance
- The ROA remained relatively stable between 12.09% and 13.06% throughout 2022. A downward trend emerged in 2023, with the ratio reaching a minimum of 8.19% in December 2023, coinciding with the period of net income instability. From March 2024 onward, a sustained and accelerating recovery is observed, with ROA climbing to 21.68% by March 2026. This trajectory indicates a substantial improvement in operational efficiency and a heightened ability to generate profit from every dollar of assets employed.